Effects of delayed treatment with transforming growth factor-β soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters

Qingjian Wang, Dallas M. Hyde, Philip J. Gotwals, Shri N. Giri

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Transforming growth factor-β (TGF-β) plays a pivotal role in an exaggerated synthesis and accumulation of collagen in fibrotic disorders of many organs. We have previously demonstrated that repeated intratracheal (IT) instillation of TGF-β soluble receptor (TR) in hamsters markedly decreased the bleomycin (BL)-induced lung fibrosis in response to a single dose. The present study was carried out in a 3-dose BL-hamster model of lung fibrosis to better evaluate the therapeutic potential of TR. Three doses of BL (2.5, 2.0, and 1.5 U/4 mL/kg) or an equivalent volume of isotonic saline was administered IT consecutively at weekly intervals, and phosphate-buffered saline (PBS) or TR (4 nmol/0.3 mL/hamster) by the same route twice a week, starting after the 2nd BL or 3rd BL dose. Twenty-one days after the 3rd dose of BL instillation, the hamsters were killed for bronchoalveolar lavage (BAL) and biochemical and histopathological analyses. The results showed that treatment with TR starting after either the 2nd or 3rd dose of BL caused significant reduction in BL-induced lung fibrosis, as demonstrated by marked decreases in the hydroxyproline level and prolyl hydroxylase activity of the lungs. Histopathological evaluation of the lungs also revealed that the hamsters in both BL + TR groups had markedly fewer fibrotic lesions than hamsters in BL + PBS group. These results demonstrate the beneficial effects of delayed treatment with TR in attenuating the progression of ongoing fibrotic process and suggest its potential therapeutic uses in the management of lung fibrosis in humans.

Original languageEnglish (US)
Pages (from-to)405-417
Number of pages13
JournalExperimental Lung Research
Volume28
Issue number6
DOIs
StatePublished - 2002

Fingerprint

Growth Factor Receptors
Bleomycin
Transforming Growth Factors
Cricetinae
Fibrosis
Lung
Therapeutics
Phosphates
Prolyl Hydroxylases
Hydroxyproline
Bronchoalveolar Lavage
Therapeutic Uses
Collagen
indium-bleomycin

Keywords

  • Bleomycin
  • Hamsters
  • Lung fibrosis
  • TGF-β soluble receptor

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Effects of delayed treatment with transforming growth factor-β soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters. / Wang, Qingjian; Hyde, Dallas M.; Gotwals, Philip J.; Giri, Shri N.

In: Experimental Lung Research, Vol. 28, No. 6, 2002, p. 405-417.

Research output: Contribution to journalArticle

Wang, Qingjian ; Hyde, Dallas M. ; Gotwals, Philip J. ; Giri, Shri N. / Effects of delayed treatment with transforming growth factor-β soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters. In: Experimental Lung Research. 2002 ; Vol. 28, No. 6. pp. 405-417.
@article{98c1abf548544aca91c6fa6ed51db4a2,
title = "Effects of delayed treatment with transforming growth factor-β soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters",
abstract = "Transforming growth factor-β (TGF-β) plays a pivotal role in an exaggerated synthesis and accumulation of collagen in fibrotic disorders of many organs. We have previously demonstrated that repeated intratracheal (IT) instillation of TGF-β soluble receptor (TR) in hamsters markedly decreased the bleomycin (BL)-induced lung fibrosis in response to a single dose. The present study was carried out in a 3-dose BL-hamster model of lung fibrosis to better evaluate the therapeutic potential of TR. Three doses of BL (2.5, 2.0, and 1.5 U/4 mL/kg) or an equivalent volume of isotonic saline was administered IT consecutively at weekly intervals, and phosphate-buffered saline (PBS) or TR (4 nmol/0.3 mL/hamster) by the same route twice a week, starting after the 2nd BL or 3rd BL dose. Twenty-one days after the 3rd dose of BL instillation, the hamsters were killed for bronchoalveolar lavage (BAL) and biochemical and histopathological analyses. The results showed that treatment with TR starting after either the 2nd or 3rd dose of BL caused significant reduction in BL-induced lung fibrosis, as demonstrated by marked decreases in the hydroxyproline level and prolyl hydroxylase activity of the lungs. Histopathological evaluation of the lungs also revealed that the hamsters in both BL + TR groups had markedly fewer fibrotic lesions than hamsters in BL + PBS group. These results demonstrate the beneficial effects of delayed treatment with TR in attenuating the progression of ongoing fibrotic process and suggest its potential therapeutic uses in the management of lung fibrosis in humans.",
keywords = "Bleomycin, Hamsters, Lung fibrosis, TGF-β soluble receptor",
author = "Qingjian Wang and Hyde, {Dallas M.} and Gotwals, {Philip J.} and Giri, {Shri N.}",
year = "2002",
doi = "10.1080/01902140290096700",
language = "English (US)",
volume = "28",
pages = "405--417",
journal = "Experimental Lung Research",
issn = "0190-2148",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Effects of delayed treatment with transforming growth factor-β soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters

AU - Wang, Qingjian

AU - Hyde, Dallas M.

AU - Gotwals, Philip J.

AU - Giri, Shri N.

PY - 2002

Y1 - 2002

N2 - Transforming growth factor-β (TGF-β) plays a pivotal role in an exaggerated synthesis and accumulation of collagen in fibrotic disorders of many organs. We have previously demonstrated that repeated intratracheal (IT) instillation of TGF-β soluble receptor (TR) in hamsters markedly decreased the bleomycin (BL)-induced lung fibrosis in response to a single dose. The present study was carried out in a 3-dose BL-hamster model of lung fibrosis to better evaluate the therapeutic potential of TR. Three doses of BL (2.5, 2.0, and 1.5 U/4 mL/kg) or an equivalent volume of isotonic saline was administered IT consecutively at weekly intervals, and phosphate-buffered saline (PBS) or TR (4 nmol/0.3 mL/hamster) by the same route twice a week, starting after the 2nd BL or 3rd BL dose. Twenty-one days after the 3rd dose of BL instillation, the hamsters were killed for bronchoalveolar lavage (BAL) and biochemical and histopathological analyses. The results showed that treatment with TR starting after either the 2nd or 3rd dose of BL caused significant reduction in BL-induced lung fibrosis, as demonstrated by marked decreases in the hydroxyproline level and prolyl hydroxylase activity of the lungs. Histopathological evaluation of the lungs also revealed that the hamsters in both BL + TR groups had markedly fewer fibrotic lesions than hamsters in BL + PBS group. These results demonstrate the beneficial effects of delayed treatment with TR in attenuating the progression of ongoing fibrotic process and suggest its potential therapeutic uses in the management of lung fibrosis in humans.

AB - Transforming growth factor-β (TGF-β) plays a pivotal role in an exaggerated synthesis and accumulation of collagen in fibrotic disorders of many organs. We have previously demonstrated that repeated intratracheal (IT) instillation of TGF-β soluble receptor (TR) in hamsters markedly decreased the bleomycin (BL)-induced lung fibrosis in response to a single dose. The present study was carried out in a 3-dose BL-hamster model of lung fibrosis to better evaluate the therapeutic potential of TR. Three doses of BL (2.5, 2.0, and 1.5 U/4 mL/kg) or an equivalent volume of isotonic saline was administered IT consecutively at weekly intervals, and phosphate-buffered saline (PBS) or TR (4 nmol/0.3 mL/hamster) by the same route twice a week, starting after the 2nd BL or 3rd BL dose. Twenty-one days after the 3rd dose of BL instillation, the hamsters were killed for bronchoalveolar lavage (BAL) and biochemical and histopathological analyses. The results showed that treatment with TR starting after either the 2nd or 3rd dose of BL caused significant reduction in BL-induced lung fibrosis, as demonstrated by marked decreases in the hydroxyproline level and prolyl hydroxylase activity of the lungs. Histopathological evaluation of the lungs also revealed that the hamsters in both BL + TR groups had markedly fewer fibrotic lesions than hamsters in BL + PBS group. These results demonstrate the beneficial effects of delayed treatment with TR in attenuating the progression of ongoing fibrotic process and suggest its potential therapeutic uses in the management of lung fibrosis in humans.

KW - Bleomycin

KW - Hamsters

KW - Lung fibrosis

KW - TGF-β soluble receptor

UR - http://www.scopus.com/inward/record.url?scp=0036348489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036348489&partnerID=8YFLogxK

U2 - 10.1080/01902140290096700

DO - 10.1080/01902140290096700

M3 - Article

VL - 28

SP - 405

EP - 417

JO - Experimental Lung Research

JF - Experimental Lung Research

SN - 0190-2148

IS - 6

ER -